Founded in 2001, Selexis is a scientific pioneer in mammalian (suspension-adapted CHO-K1) cell line generation that helps partners to develop innovative therapies. Its cell line expression technologies can
OMS721, a human monoclonal antibody selectively targets MASP-2 which expands to mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway of the complement system. The breakthrough
Tanezumab is an investigational humanized monoclonal antibody, which can selectively target, bind and inhibit nerve growth factor (NGF). Through inhibiting NGF, tanezumab will enable to prevent pain signals produced
The company plans to discontinue the HCV candidate development, after the completion of the one remaining clinical study that is expected in July this year. Regulus has decided to terminate
The removal was sought after concerns that the risks associated with consuming the drug outweighed its benefits, stated the FDA. In fact, it marks the first time that the
J&J signed an agreement in January this year to acquire Actelion, which develops and commercializes new drugs for diseases with significant unmet medical need. With the EC approval, the
A company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group will acquire the business from Valeant. iNova is engaged in the
The investigational oral agent upadacitinib was evaluated in a phase 3 clinical trial, dubbed SELECT-NEXT, in patients with moderate to severe RA who did not respond adequately to treatment with
Excluding Japan, Grünenthal will hold the global rights to Zomig, which is developed for the acute treatment of migraines and cluster headaches. Zomig was approved to treat migraine
Aristada is an extended-release injectable atypical antipsychotic which after entering into the body gets converted to aripiprazole. The atypical antipsychotic has now been approved by FDA in four
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.